Non-invasive imaging biomarkers for liver steatosis in non-alcoholic fatty liver disease: present and future

키워드

참고문헌 (93)

1. Younossi ZM, "Global epidemiology of nonalcoholic fatty liver disease-metaanalytic assessment of prevalence, incidence, and outcomes", Hepatology, 64, pp.73~84 (2016)
2. Ito T, "The epidemiology of NAFLD and lean NAFLD in Japan : a metaanalysis with individual and forecasting analysis, 1995-2040", Hepatol Int, 15, pp.366~379 (2021)
3. Seung Ha Park, "Trends in the prevalence of chronic liver disease in the Korean adult population, 1998–2017", Clinical and Molecular Hepatology, 26(2), pp.209~215 (2020), 대한간학회[DOI]
4. Ludwig J, "Nonalcoholic steatohepatitis : Mayo Clinic experiences with a hitherto unnamed disease", Mayo Clin Proc, 55, pp.434~438 (1980)
5. Schaffner F, "Nonalcoholic fatty liver disease", Prog Liver Dis, 8, pp.283~298 (1986)
6. Matteoni CA, "Nonalcoholic fatty liver disease : a spectrum of clinical and pathological severity", Gastroenterology, 116, pp.1413~1419 (1999)
7. Chalasani N, "The diagnosis and management of nonalcoholic fatty liver disease : practice guidance from the American Association for the Study of Liver Diseases", Hepatology, 67, pp.328~357 (2018)
8. Bedossa P, "Pathology of non-alcoholic fatty liver disease", Liver Int, 37(Suppl 1), pp.85~89 (2017)
9. Rockey DC, "Liver biopsy", Hepatology, 49, pp.1017~1044 (2009)
10. Hwi Young Kim, "Recent advances in nonalcoholic fatty liver disease metabolomics", Clinical and Molecular Hepatology, 27(4), pp.553~559 (2021), 대한간학회[DOI]
11. Caussy C, "Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials", Hepatology, 68, pp.763~772 (2018)
12. de Lédinghen V, "Controlled attenuation parameter for the diagnosis of steatosis in non-alcoholic fatty liver disease", J Gastroenterol Hepatol, 31, pp.848~855 (2016)
13. Theresa J. Hydes, "Evidence-based clinical advice for nutrition and dietary weight loss strategies for the management of NAFLD and NASH", Clinical and Molecular Hepatology, 26(4), pp.383~400 (2020), 대한간학회[DOI]
14. Kyung-Soo Kim, "Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 26(4), pp.430~443 (2020), 대한간학회[DOI]
15. Kleiner DE, "Design and validation of a histological scoring system for nonalcoholic fatty liver disease", Hepatology, 41, pp.1313~1321 (2005)
16. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.56, 951~963
17. Tokushige K, "Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease", nonalcoholic steatohepatitis 2020, 2021, pp.51, 1013~1025
18. Rafiq N, "Long-term follow-up of patients with nonalcoholic fatty liver", Clin Gastroenterol Hepatol, 7, pp.234~238 (2009)
19. Angulo P, "Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease", Gastroenterology, 149, pp.389~397 (2015)
20. Loomba R, "The hierarchical model of NAFLD : prognostic significance of histologic features in NASH", Gastroenterology, 149, pp.278~281 (2015)
21. Dulai PS, "Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease : systematic review and meta-analysis", Hepatology, 65, pp.1557~1565 (2017)
22. Hagström H, "Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD", J Hepatol, 67, pp.1265~1273 (2017)
23. Singh S, "Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis : a systematic review and meta-analysis of paired-biopsy studies", Clin Gastroenterol Hepatol, 13, pp.643~654 (2015)
24. Simon TG, "Mortality in biopsy-confirmed nonalcoholic fatty liver disease : results from a nationwide cohort", Gut, 70, pp.1375~1382 (2021)
25. Joseph AE, "Ultrasound in the detection of chronic liver disease(the"bright liver")", Br J Radiol, 52, pp.184~188 (1979)
26. Yajima Y, "Ultrasonographical diagnosis of fatty liver : significance of the liver-kidney contrast", Tohoku J Exp Med, 139, pp.43~50 (1983)
27. Saadeh S, "The utility of radiological imaging in nonalcoholic fatty liver disease", Gastroenterology, 123, pp.745~750 (2002)
28. Hernaez R, "Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver : a meta-analysis", Hepatology, 54, pp.1082~1090 (2011)
29. Lewis JR, "Nonalcoholic fatty liver disease : a review and update", Dig Dis Sci, 55, pp.560~578 (2010)
30. Dasarathy S, "Validity of real time ultrasound in the diagnosis of hepatic steatosis : a prospective study", J Hepatol, 51, pp.1061~1067 (2009)
31. Wieckowska A, "Diagnosis of nonalcoholic fatty liver disease : invasive versus noninvasive", Semin Liver Dis, 28, pp.386~395 (2008)
32. Bohte AE, "The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy : a meta-analysis", Eur Radiol, 21, pp.87~97 (2011)
33. Kondo R, "Pathological findings of liver steatosis that is difficult to evaluate with ultrasound", J Med Ultrason(2001), 48, pp.515~522 (2021)
34. Hamaguchi M, "The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation", Am J Gastroenterol, 102, pp.2708~2715 (2007)
35. Sandrin L, "Transient elastography : a new noninvasive method for assessment of hepatic fibrosis", Ultrasound Med Biol, 29, pp.1705~1713 (2003)
36. Sasso M, "Controlled attenuation parameter(CAP) : a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis : preliminary study and validation in a cohort of patients with chronic liver disease from various causes", Ultrasound Med Biol, 36, pp.1825~1835 (2010)
37. de Lédinghen V, "Feasibility of liver transient elastography with FibroScan using a new probe for obese patients", Liver Int, 30, pp.1043~1048 (2010)
38. Sasso M, "Liver steatosis assessed by controlled attenuation parameter(CAP)measured with the XL probe of the FibroScan : a pilot study assessing diagnostic accuracy", Ultrasound Med Biol, 42, pp.92~103 (2016)
39. Audière S, "Improved ultrasound attenuation measurement method for the non-invasive evaluation of hepatic steatosis using FibroScan", Ultrasound Med Biol, 47, pp.3181~3195 (2021)
40. Nogami A, "Real-world assessment of SmartExam, a novel FibroScan computational method: a retrospective single-center cohort study", J Gastroenterol Hepatol (2022)[DOI]
41. Cao YT, "Accuracy of controlled attenuation parameter(CAP)and liver stiffness measurement(LSM)for assessing steatosis and fibrosis in nonalcoholic fatty liver disease : a systematic review and metaanalysis", EClinicalMedicine, 51, pp.101547~ (2022)
42. European Association for the Study of the Liver(EASL), "EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease", J Hepatol, 64, pp.1388~1402 (2016)
43. 강성희, "KASL clinical practice guidelines: Management of nonalcoholic fatty liver disease", Clinical and Molecular Hepatology, 27(3), pp.363~401 (2021), 대한간학회
44. Suzuki K, "Transient elastography for monitoring the fibrosis of nonalcoholic fatty liver disease for 4 years", Hepatol Res, 43, pp.979~983 (2013)
45. Nogami A, "Assessment of 10-year changes in liver stiffness using vibration-controlled transient elastography in non-alcoholic fatty liver disease", Hepatol Res, 49, pp.872~880 (2019)
46. Ferraioli G, "Quantification of liver fat content with the iATT algorithm: correlation with controlled attenuation parameter", Diagnostics(Basel), 12, pp.1787~ (2022)
47. Labyed Y, "Novel method for ultrasound-derived fat fraction using an integrated phantom", J Ultrasound Med, 39, pp.2427~2438 (2020)
48. Gao J, "Reliability of performing ultrasound derived SWE and fat fraction in adult livers", Clin Imaging, 80, pp.424~429 (2021)
49. Dillman JR, "Quantification of hepatic steatosis by ultrasound : prospective comparison with MRI proton density fat fraction as reference standard", AJR Am J Roentgenol, 219, pp.784~791 (2022)
50. Tada T, "Attenuation imaging based on ultrasound technology for assessment of hepatic steatosis : a comparison with magnetic resonance imaging-determined proton density fat fraction", Hepatol Res, 50, pp.1319~1327 (2020)
51. Hsu PK, "Attenuation imaging with ultrasound as a novel evaluation method for liver steatosis", J Clin Med, 10, pp.965~ (2021)
52. Ferraioli G, "Detection of liver steatosis with a novel ultrasoundbased technique : a pilot study using MRI-derived proton density fat fraction as the gold standard", Clin Transl Gastroenterol, 10, pp.e00081~ (2019)
53. Jeon SK, "Prospective evaluation of hepatic steatosis using ultrasound attenuation imaging in patients with chronic liver disease with magnetic resonance imaging proton density fat fraction as the reference standard", Ultrasound Med Biol, 45, pp.1407~1416 (2019)
54. Bae JS, "Assessment of hepatic steatosis by using attenuation imaging : a quantitative, easy-to-perform ultrasound technique", Eur Radiol, 29, pp.6499~6507 (2019)
55. Dioguardi Burgio M, "Quantification of hepatic steatosis with ultrasound : promising role of attenuation imaging coefficient in a biopsy-proven cohort", Eur Radiol, 30, pp.2293~2301 (2020)
56. Lee DH, "Accuracy of two-dimensional shear wave elastography and attenuation imaging for evaluation of patients with nonalcoholic steatohepatitis", Clin Gastroenterol Hepatol, 19, pp.797~805 (2021)
57. Sugimoto K, "The role of multiparametric US of the liver for the evaluation of nonalcoholic steatohepatitis", Radiology, 296, pp.532~540 (2020)
58. Ferraioli G, "Performance of the attenuation imaging technology in the detection of liver steatosis", J Ultrasound Med, 40, pp.1325~1332 (2021)
59. Tada T, "Usefulness of attenuation imaging with an ultrasound scanner for the evaluation of hepatic steatosis", Ultrasound Med Biol, 45, pp.2679~2687 (2019)
60. Kwon EY, "Usefulness of US attenuation imaging for the detection and severity grading of hepatic steatosis in routine abdominal ultrasonography", Clin Imaging, 76, pp.53~59 (2021)
61. 유정인, "Reproducibility of ultrasound attenuation imaging for the noninvasive evaluation of hepatic steatosis", ULTRASONOGRAPHY, 39(2), pp.121~129 (2020), 대한초음파의학회
62. Fujiwara Y, "The B-mode image-guided ultrasound attenuation parameter accurately detects hepatic steatosis in chronic liver disease", Ultrasound Med Biol, 44, pp.2223~2232 (2018)
63. Imajo K, "Utility of ultrasound-guided attenuation parameter for grading steatosis with reference to MRI-PDFF in a large cohort", Clin Gastroenterol Hepatol, 20, pp.2533~2541 (2022)
64. Mehta SR, "Non-invasive means of measuring hepatic fat content", World J Gastroenterol, 14, pp.3476~3483 (2008)
65. Zhong L, "Nonalcoholic fatty liver disease : quantitative assessment of liver fat content by computed tomography, magnetic resonance imaging and proton magnetic resonance spectroscopy", J Dig Dis, 10, pp.315~320 (2009)
66. Mellor-Crummey LE, "A comparison of the Liver Fat Score and CT liver-to-spleen ratio as predictors of fatty liver disease by HIV serostatus", J Clin Gastroenterol Hepatol, 2, pp.16~ (2018)
67. Tobari M, "Imaging of nonalcoholic steatohepatitis : advantages and pitfalls of ultrasonography and computed tomography", Intern Med, 48, pp.739~746 (2009)
68. Qayyum A, "Evaluation of diffuse liver steatosis by ultrasound, computed tomography, and magnetic resonance imaging: which modality is best?", Clin Imaging, 33, pp.110~115 (2009)
69. Lee SW, "Unenhanced CT for assessment of macrovesicular hepatic steatosis in living liver donors : comparison of visual grading with liver attenuation index", Radiology, 244, pp.479~485 (2007)
70. Raptopoulos V, "Value of dual-energy CT in differentiating focal fatty infiltration of the liver from low-density masses", AJR Am J Roentgenol, 157, pp.721~725 (1991)
71. Mendler MH, "Dual-energy CT in the diagnosis and quantification of fatty liver : limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload", J Hepatol, 28, pp.785~794 (1998)
72. Zhang PP, "Detection of fatty liver using virtual non-contrast dual-energy CT", Abdom Radiol(NY), 47, pp.2046~2056 (2022)
73. Hu L, "Hepatic steatosis is associated with abnormal hepatic enzymes, visceral adiposity, altered myocardial glucose uptake measured by 18FFDG PET", CT, 2020, pp.20, 75~
74. Longo R, "Fatty infiltration of the liver. Quantification by 1H localized magnetic resonance spectroscopy and comparison with computed tomography", Invest Radiol, 28, pp.297~302 (1993)
75. Longo R, "Proton MR spectroscopy in quantitative in vivo determination of fat content in human liver steatosis", J Magn Reson Imaging, 5, pp.281~285 (1995)
76. Thomsen C, "Quantification of liver fat using magnetic resonance spectroscopy", Magn Reson Imaging, 12, pp.487~495 (1994)
77. Szczepaniak LS, "Measurement of intracellular triglyceride stores by H spectroscopy : validation in vivo", Am J Physiol, 276, pp.E977~E989 (1999)
78. Mehta SR, "Proton magnetic resonance spectroscopy and ultrasound for hepatic fat quantification", Hepatol Res, 40, pp.399~406 (2010)
79. Guiu B, "Quantification of liver fat content : comparison of triple-echo chemical shift gradient-echo imaging and in vivo proton MR spectroscopy", Radiology, 250, pp.95~102 (2009)
80. Springer F, "Liver fat content determined by magnetic resonance imaging and spectroscopy", World J Gastroenterol, 16, pp.1560~1566 (2010)
81. Raptis DA, "MRI : the new reference standard in quantifying hepatic steatosis?", Gut, 61, pp.117~127 (2012)
82. Roldan-Valadez E, "In vivo 3T spectroscopic quantification of liver fat content in nonalcoholic fatty liver disease : correlation with biochemical method and morphometry", J Hepatol, 53, pp.732~737 (2010)
83. Nakajima A, "Randomised clinical trial : Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator(SPPARMα), versus placebo in patients with non-alcoholic fatty liver disease", Aliment Pharmacol Ther, 54, pp.1263~1277 (2021)
84. Noureddin M, "Utility of magnetic resonance imaging versus histology for quantifying changes in liver fat in nonalcoholic fatty liver disease trials", Hepatology, 58, pp.1930~1940 (2013)
85. Idilman IS, "Impact of sequential proton density fat fraction for quantification of hepatic steatosis in nonalcoholic fatty liver disease", Scand J Gastroenterol, 49, pp.617~624 (2014)
86. Park CC, "Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease", Gastroenterology, 152, pp.598~607 (2017)
87. Konerman MA, "Pharmacotherapy for NASH : current and emerging", J Hepatol, 68, pp.362~375 (2018)
88. Liu F, "qFIBS : an automated technique for quantitative evaluation of fibrosis, inflammation, ballooning, and steatosis in patients with nonalcoholic steatohepatitis", Hepatology, 71, pp.1953~1966 (2020)
89. Taylor-Weiner A, "A machine learning approach enables quantitative measurement of liver histology and disease monitoring in NASH", Hepatology, 74, pp.133~147 (2021)
90. Brunt EM, "Complexity of ballooned hepatocyte feature recognition : defining a training atlas for artificial intelligence-based imaging in NAFLD", J Hepatol, 76, pp.1030~1041 (2022)
91. Decharatanachart P, "Application of artificial intelligence in chronic liver diseases : a systematic review and meta-analysis", BMC Gastroenterol, 21, pp.10~ (2021)
92. Eslam M, "A new definition for metabolic dysfunctionassociated fatty liver disease : an international expert consensus statement", J Hepatol, 73, pp.202~209 (2020)
93. Seong Hee Kang, "From nonalcoholic fatty liver disease to metabolic-associated fatty liver disease: Big wave or ripple?", Clinical and Molecular Hepatology, 27(2), pp.257~269 (2021), 대한간학회[DOI]

관련 논문AI추천